Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents

Abstract

(<italic>E</italic>)-3-[3-(Pyridin-3/4-yl)-1-(phenyl/sulfonylmethylphenyl)-1<italic>H</italic>-pyrazol-4-yl]acrylamides were synthesized and their COX-1 and COX-2 inhibitory, antiplatelet and cytotoxic activities were evaluated.